The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback